Health Care & Life Sciences » Biotechnology | Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S | Cash Flow

Fiscal year is January-December. All values DKK Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
136,135.00
58,604.00
197,100.00
193,621.70
55,126.30
36,870.60
Depreciation, Depletion & Amortization
1,315.00
993.00
1,474.00
1,399.90
1,351.90
1,219.30
Other Funds
12,367.00
6,562.00
18,422.00
42,334.60
19,527.30
23,344.20
Funds from Operations
122,453.00
51,049.00
177,204.00
149,887.20
34,247.00
58,995.50
Changes in Working Capital
35,294.00
26,194.00
144.00
38,949.10
16,599.20
12,174.40
Net Operating Cash Flow
157,747.00
77,243.00
177,348.00
188,836.30
50,846.20
71,169.90
Capital Expenditures
1,055.00
2,547.00
324.00
1,184.60
3,719.50
Net Investing Cash Flow
1,055.00
2,547.00
324.00
1,184.60
3,719.50
Issuance/Reduction of Debt, Net
3,665.00
-
-
92,988.00
78,782.00
Net Financing Cash Flow
3,227.00
989.00
323.00
107,559.40
82,006.90
Net Change in Cash
168,182.00
58,218.00
162,776.00
83,484.60
29,063.50
Free Cash Flow
158,802.00
79,790.00
177,672.00
190,020.90
54,565.70
Change in Capital Stock
438.00
989.00
323.00
14,571.40
3,224.90
Exchange Rate Effect
6,153.00
20,583.00
14,573.00
1,023.00
1,622.30

About Veloxis Pharmaceuticals A/S

View Profile
Address
Amerika Plads 37
Copenhagen CR 2100
Denmark
Employees -
Website http://www.veloxis.com
Updated 07/08/2019
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.